Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer

被引：5
作者：
Ferretti, Gianluigi [1 ]
Papaldo, Paola [1 ]
Fabi, Alessandra [1 ]
Carlini, Paolo [1 ]
Felici, Alessandra [1 ]
Cognetti, Francesco [1 ]
机构：
[1] Regina Elena Inst Canc Res, Div Med Oncol A, I-00144 Rome, Italy
来源：
ONCOLOGIST | 2006年 / 11卷 / 07期
关键词：
D O I：
10.1634/theoncologist.11-7-853
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：853 / 854
页数：2
相关论文
共 7 条
  • [1] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    Burstein, HJ
    Harris, LN
    Marcom, PK
    Lambert-Falls, R
    Havlin, K
    Overmoyer, B
    Friedlander, RJ
    Gargiulo, J
    Strenger, R
    Vogel, CL
    Ryan, PD
    Ellis, MJ
    Nunes, RA
    Bunnell, CA
    Campos, SM
    Hallor, M
    Gelman, R
    Winer, EP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2889 - 2895
  • [2] Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era
    Colozzaa, Mariantonietta
    de Azambuja, Evandro
    Cardoso, Fatima
    Bernard, Chantal
    Piccart, Martine J.
    [J]. ONCOLOGIST, 2006, 11 (02) : 111 - 125
  • [3] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Joensuu, H
    Kellokumpu-Lehtinen, P
    Bono, P
    Alanko, T
    Kataja, V
    Asola, R
    Utriainen, T
    Kokko, R
    Hemminki, A
    Tarkkanen, M
    Turpeenniemi-Hujanen, T
    Jyrkkiö, S
    Flander, M
    Helle, L
    Ingalsuo, S
    Johansson, K
    Jääskeläinen, A
    Pajunen, M
    Rauhala, M
    Kaleva-Kerola, J
    Salminen, T
    Leinonen, M
    Elomaa, I
    Isola, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) : 809 - 820
  • [4] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
    Marty, M
    Cognetti, F
    Maraninchi, D
    Snyder, R
    Mauriac, L
    Tubiana-Hulin, M
    Chan, S
    Grimes, D
    Antón, A
    Lluch, A
    Kennedy, J
    O'Byrne, K
    Conte, P
    Green, M
    Ward, C
    Mayne, K
    Extra, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4265 - 4274
  • [5] A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
    Papaldo, P
    Fabi, A
    Ferretti, G
    Mottolese, M
    Cianciulli, AM
    Di Cocco, B
    Pino, MS
    Carlini, P
    Di Cosimo, S
    Sacchi, I
    Sperduti, I
    Nardoni, C
    Cognetti, F
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (04) : 630 - 636
  • [6] Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    Pegram, MD
    Konecny, GE
    O'Callaghan, C
    Beryt, M
    Pietras, R
    Slamon, DJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (10): : 739 - 749
  • [7] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1673 - 1684
1